Solid lipid nanoparticles for ocular drug delivery

Seyfoddin, Ali; Shaw, John; Al‐Kassas, Raida

doi:10.3109/10717544.2010.483257

Cited by 191 publications

(107 citation statements)

References 106 publications

Supporting

Mentioning

106

Contrasting

Order By: Relevance

“…Solid lipid nanoparticles (NPs) are colloidal particles composed of different types of physiological lipids and exhibit a size range between 50 and 400 nm (Hou et al, 2003;Seyfoddin et al, 2010). They are prepared mainly with phospholipids and solid lipids, which are generally considered safe, biocompatible, and biodegradable (Thukral et al, 2014;Misra et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: Sialic acid-modified solid lipid nanoparticles as vascular endothelium-targeting carriers for ischemia-reperfusion-induced acute renal injury

2017

Drug Delivery

View full text Add to dashboard Cite

, and the mechanism is associated with the specific binding between SA and E-selectin receptor expressed on the inflamed vascular endothelial cells. Bio-distribution results further demonstrated the enhanced renal accumulation of DXM is achieved in AKI mice treated with SA-NPs, and its content is 2.70-and 5.88-fold higher than those treated with DXM and NPs at 6 h after intravenous administration, respectively. Pharmacodynamic studies demonstrate SANPs effectively ameliorate renal functions in AKI mice, as reflected by improved blood biochemical indexes, histopathological changes, oxidative stress levels and pro-inflammatory cytokines. Moreover, SA-NPs cause little negative effects on lymphocyte count and bone mineral density while DXM leads to severe osteoporosis. It is concluded that SA-NPs provide an efficient and targeted delivery of DXM for ischemia-reperfusion-induced injury-induced AKI, with improved therapeutic outcomes and reduced adverse effects.ARTICLE HISTORY

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: Sialic acid-modified solid lipid nanoparticles as vascular endothelium-targeting carriers for ischemia-reperfusion-induced acute renal injury

2017

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…All the ophthalmic products should be sterile, and physically and chemically stable on storage. 32 Indomethacin has been reported to undergo pH-dependent hydrolysis to 5-methoxy-2-methyl-indol-3-acetic acid and p-cholorobenzoic acid. 1,33 The ability of SLNs to reduce hydrolysis, oxidation, and photodegradation of drugs as a result of incorporation into solid lipid matrices is well documented.…”

mentioning

confidence: 99%

Indomethacin-Loaded Solid Lipid Nanoparticles for Ocular Delivery: Development, Characterization, and In Vitro Evaluation

Hippalgaonkar

Adelli²,

Hippalgaonkar

et al. 2013

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

Purpose: The goal of this study was to develop and characterize indomethacin-loaded solid lipid nanoparticles (IN-SLNs; 0.1% w/v) for ocular delivery. Methods: Various lipids, homogenization pressures/cycles, Tween 80 fraction in the mixture of surfactants (Poloxamer 188 and Tween 80; total surfactant concentration at 1% w/v), and pH were investigated in the preparation of the IN-SLNs. Compritol Ò 888 ATO was selected as the lipid phase for the IN-SLNs, as indomethacin exhibited a highest distribution coefficient and solubility in this phase. Results: Homogenization at 15,000 psi for 6 cycles resulted in the smallest particle size. Increase in the Poloxamer 188 fraction resulted in decrease in the entrapment efficiency (EE). The mean particle size, polydispersity index, zeta-potential, and EE of the optimized formulation were 140 nm, 0.16, -21 mV, and 72.0%, respectively. INSLNs were physically stable post-sterilization and on storage for a period of 1 month (last timepoint tested). A dramatic increase in the chemical stability and in vitro corneal permeability of indomethacin was observed with the IN-SLN formulation in comparison to the indomethacin solution-(0.1% w/v) and indomethacin hydroxypropyl-beta-cyclodextrin-based formulations (0.1% w/v). Conclusion: Results from this study suggest that topical IN-SLNs could significantly improve ocular bioavailability of indomethacin.

show abstract

“…The in-vitro release studies agree with the solid lipid nanoparticles characteristic feature. The SLN are associated with burst release of drugs [38] which is a disadvantage turned into advantage in this case because of the tear and blinking mechanism. The burst release is an advantage in this case because of the major drug release over a short period of is because of the drug adsorption over the surface of nanoparticle and not in the core which will be easily available for the treatment of cataract.…”

Section: Discussionmentioning

confidence: 99%

An approach to revolutionize cataract treatment by enhancing drug probing through intraocular cell line

Liu

Huang

2018

Libyan Journal of Medicine

View full text Add to dashboard Cite

The purpose of this study is to prepare and characterize solid lipid nanoparticles (SLN) of N-Acetyl Carnosine (NAC) to treat cataract since surgery necessitates equipments and professional help. Cataract is believed to be formed by the biochemical approach where the crystalline eye proteins lose solubility and forms high molecular weight masses. Added advantages of SLN of NAC (henceforth referred as SLN-NAC) in the study are reduced size, sustained release and better corneal penetration of drug. The method of preparation of SLN-NAC by Mill’s method is unique in itself.The size of the SLN-NAC was 75 ± 10 nm in the range of ideal for penetration. The in-vitro release study and the SLN-NAC formulations prepared with Mill’s method demonstrated sustained release up to 24 h following an initial burst after 1 h. The zeta potential of the prepared formulation was −22.1 ± 1 mV. Corneal permeation studies using goat corneas indicate that SLN-NAC penetration rate was higher than those from NAC eye drops. Corneal hydration studies indicated that the formulation caused no harm to the corneal cells.Therefore it may be concluded that SLN-NAC may revolutionize cataract treatment and reversal by improving drug permeation, reducing toxicity and no damage to corneal tissue.

show abstract

Solid lipid nanoparticles for ocular drug delivery

Cited by 191 publications

References 106 publications

RETRACTED ARTICLE: Sialic acid-modified solid lipid nanoparticles as vascular endothelium-targeting carriers for ischemia-reperfusion-induced acute renal injury

RETRACTED ARTICLE: Sialic acid-modified solid lipid nanoparticles as vascular endothelium-targeting carriers for ischemia-reperfusion-induced acute renal injury

Indomethacin-Loaded Solid Lipid Nanoparticles for Ocular Delivery: Development, Characterization, and In Vitro Evaluation

An approach to revolutionize cataract treatment by enhancing drug probing through intraocular cell line

Contact Info

Product

Resources

About